Effects of psychotropic drugs on cell proliferation and differentiation

Biochemical Pharmacology

Volumn 58, Issue 8, 1999, Pages 1229-1236

  Nordenberg, Jardena ^a,d   Fenig, Eyal ^a,b   Landau, Marina ^a   Weizman, Ronit ^a,c   Weizman, Abraham ^a,d  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antiepileptics; Benzodiazepines; Cell proliferation; Growth and differentiation; Mood stabilizers; Normal and cancer cells; Phenothiazines

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; BROMAZEPAM; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CLONAZEPAM; CLORAZEPATE; CLOZAPINE; DIAZEPAM; FLUOXETINE; FLUPHENAZINE; LITHIUM CHLORIDE; MEDAZEPAM; MIDAZOLAM; PENFLURIDOL; PERPHENAZINE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PSYCHOTROPIC AGENT; RISPERIDONE; VALPROIC ACID; ZIMELDINE;

ANTINEOPLASTIC ACTIVITY; ANXIETY; CANCER; CELL PROLIFERATION; DEPRESSION; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; REVIEW;

EID: 0032856051     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00156-2     Document Type: Article

References (76)

1. Bruera E., Neumann C.M. The uses of psychotropics in symptom management in advanced cancer. Psychooncology. 7:1998;346-358.
2. Derogatis L.R., Morrow G.R., Fetting J., Penman D., Piasetsky S., Shmale A.M., Henricks M., Carnicke C.L. Jr. The prevalence of psychiatric disorders among cancer patients. JAMA. 249:1983;751-757.
3. Greenberg D.B. Strategic use of benzodiazepines in cancer patients. Oncology (Huntingt). 5:1991;83-88.
4. Kris M.G., Pisters K.M., Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 2:1994;297-300.
5. Goodman M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Oncol Nurs Forum. 24:(Suppl 7):1997;20-32.
6. Kloke M., Hoffken K., Olbrich H., Schmidt C.G. Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients. Onkologie. 14:1991;40-43.
7. Camins A., Diez-Fernandez C., Pujadas E., Camarasa J., Escubedo E. A new aspect of the antiproliferative action of peripheral type benzodiazepine receptor ligands. Eur J Pharmacol. 272:1995;289-292.
8. Stepien H, Pawlikowska A and Pawlikowski M, Effects of benzodiazepines on thymus cell proliferation. Thymus 12: 117-121, 1988-89.
9. Regan C.M., Gorman A.M., Larsson O.M., Maguire C., Martin M.L., Schousboe A., Williams D.C. In vitro screening for anticonvulsant-induced teratogenesis in neuronal primary culture and cell lines. Int J Dev Neurosci. 8:1990;143-150.
10. Miernick A., Santa-Marcia A., Marano F. The antimitotic activities of some benzodiazepines. Experientia. 42:1986;956-958.
11. Bruce J.H., Ramirez A.M., Lin L., Oracion A., Agarwal R.P., Norenberg M.D. Peripheral-type benzodiazepines inhibit proliferation of astrocytes in culture. Brain Res. 564:1994;167-170.
12. Neary J.T., Jorgensen S.L., Oracion A.M., Bruce J.H., Norenberg M.D. Inhibition of growth factor-induced DNA synthesis in astrocytes by ligands of peripheral-type benzodiazepine receptors. Brain Res. 675:1995;27-30.
13. Lafi A., Parry J.M. A study of the induction of aneuploidy and chromosome aberrations after diazepam, medazepam, midazolam and bromazepam treatment. Mutagenesis. 3:1988;23-27.
14. Gorman A.M., O'Beirne G.N., Regan C.M., Williams D.C. Antiproliferative action of benzodiazepines in cultured brain cells is not mediated through the peripheral-type benzodiazepine acceptor. J Neurochem. 53:1989;849-855.
15. 1 phase of the cell cycle. Brain Res. 590:1992;74-80.
16. Sidi Y., Beery E., Panet C., Wasserman L., Novogrodsky A., Nordenberg J. Growth inhibition and induction of phenotypic alterations by tiazofurin Differential effects on breast cancer and HB-100 breast cell lines . Eur J Cancer Clin Oncol. 25:1989;883-889.
17. 1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals. Cell Growth Differ. 9:1998;465-474.
18. Ikezaki K., Black K.L. Stimulation of cell growth and DNA synthesis by peripheral benzodiazepine. Cancer Lett. 49:1990;115-120.
19. Kunert-Radek J., Stepien H., Pawlikowski H. Inhibition of rat pituitary cell proliferation by benzodiazepines in vitro. Neuroendocrinology. 59:1994;92-96.
20. Crocker C.E., Niles L.P. Benzodiazepine-induced inhibition of human malignant melanoma (M-6) cell growth. Anticancer Res. 16:1996;1259-1263.
21. Solowey W.E., Pestka S., Spector S., Fryer R.I., Fisher P.B. Peripheral-acting benzodiazepines inhibit the growth of human melanoma cells and potentiate the antiproliferative activity of recombinant interferons. J Interferon Res. 10:1990;269-280.
22. Curran T., Morgan J.I. Superinduction of c-fos by nerve growth factor in the presence of peripherally active benzodiazepines. Science. 229:1985;1265-1268.
23. Miller L.G., Tischler A.S., Jumblatt J.E., Greenblatt D.J. Benzodiazepine binding sites on PC12 cells Modulation by nerve growth factor and forskolin . Neurosci Lett. 89:1988;342-348.
24. Black K.L., Shiraishi T., Ikezak K., Tabuchi K., Becker D.F. Peripheral benzodiazepine stimulates secretion of growth hormone and mitochondrial proliferation in pituitary tumor GH3 cells. Neurol Res. 16:1994;74-80.
25. Mak N.K., Szeto Y.Y., Fung M.C., Leung K.N., Kwan S.K. Effects of midazolam on the differentiation of murine myeloid leukemia cells. Chemotherapy. 43:1997;272-281.
26. Landau M., Weizman A., Zoref-Shani E., Beery E., Wasserman L., Landau O., Gavish M., Brenner S., Nordenberg J. Antiproliferative and differentiating effects of benzodiazepine receptor ligands on B16 melanoma cells. Biochem Pharmacol. 56:1998;1029-1034.
27. Katz Y., Ben-Baruch G., Kloog Y., Menczer J., Gavish M. Increased density of peripheral benzodiazepine-binding sites in ovarian carcinoma as compared with benign ovarian tumours and normal ovaries. Clin Sci (Colch). 78:1990;155-159.
28. Ramseier H., Lichtensteiger W., Schlumpf M. In vitro inhibition of cellular immune responses by benzodiazepines and PK 11195. Effects on mitogen- and alloantigen-driven lymphocyte proliferation and on IL-1, IL-2 synthesis and IL-2 receptor expression. Immunopharmacol Immunotoxicol. 15:1993;557-582.
29. Ehret A., Westendorp M.O., Herr I., Debatin K.M., Heeney J.L., Frank R., Krammer P.H. Resistance of chimpanzee T cells to human immunodeficiency virus type I Tat-enhanced oxidative stress and apoptosis. J Virol. 70:1996;6502-6507.
30. L-pez-Girona A., Colomer J., Pujol M.J., Bachs O., Agell N. Calmodulin regulates DNA polymerase α activity during proliferative activation of NRK cells. Biochem Biophys Res Commun. 184:1992;1517-1523.
31. Komoda T., Ikeda E., Nakatani Y., Sakagisyi Y., Mead N., Kato T., Kumegawa M. Inhibitory effect of phenothiazine derivatives on bone in vivo and osteoblastic cells in vitro. Biochem Pharmacol. 34:1985;3885-3889.
32. Grief F., Soroff H.S., Albers K.M., Taichman L.B. The effect of trifluoperazine, a calmodulin antagonist, on the growth of normal and malignant epidermal keratinocytes in culture. Eur J Cancer Clin Oncol. 25:1989;19-26.
33. Niczyporuk W., Krajewska-Kulak E., Zimnoch L. Preliminary study on the effect of the selected calmodulin antagonists on the skin. Rocz Akad Med Bialymst. 41:1996;515-524.
34. Stringer B.M., Rowson J., Greer W., Wynford-Thomas D., Williams E.D. Effect of sustained serum prolactin elevation on breast epithelial and myoepithelial proliferation. Cell Tissue Kinet. 23:1990;17-30.
35. Schleuning M., Brumme V., Wilmanns W. Growth inhibition of human leukemic cell lines by the phenothiazine derivate fluphenazine. Anticancer Res. 13:1993;599-602.
36. Hait W.N., Lee A.L. Characteristics of the cytotoxic effects of the phenothiazine class of calmodulin antagonists. Biochem Pharmacol. 34:1985;3973-3978.
37. Hait W.N., Grais L., Benz C., Cadman E.C. Inhibition of growth of leukemic cells by inhibitors of calmodulin Phenothiazines and melittin . Cancer Chemother Pharmacol. 14:1985;202-205.
38. Glass-Marmor L., Morgenstern H., Beitner R. Calmodulin antagonists decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability of melanoma cells. Eur J Pharmacol. 313:1996;265-271.
39. Glass-Marmor L., Beitner R. Detachment of glycolytic enzymes from cytoskeleton of melanoma cells induced by calmodulin antagonists. Eur J Pharmacol. 328:1997;241-248.
40. Zhu H.G., Tayeh I., Israel L., Castagna M. Different susceptibility of lung cell lines to inhibitors of tumor promotion and inducers of differentiation. J Biol Regul Homeost Agents. 5:1991;52-58.
41. Sutherland R.L., Watts C.K., Hall R.E., Ruenitz P.C. Mechanisms of growth inhibition by nonsteroidal antiestrogens in human breast cancer cells. J Steroid Biochem. 27:1987;891-897.
42. Motohashi N., Sakagami H., Kamata K., Yamamoto Y. Cytotoxicity and differentiation-inducing activity of phenothiazine and benzo[a]phenothiazine derivatives. Anticancer Res. 11:1991;1933-1937.
43. Lee G.L., Hait W.M. Inhibition of growth of C6 astrocytoma cells by inhibitors of calmodulin. Life Sci. 36:1985;347-354.
44. Marushige Y., Marushige K., Koestner A. Chemical control of growth and morphological characteristics of anaplastic glioma cells. Anticancer Res. 9:1989;1729-1735.
45. Hait W.N., Gesmonde J.F., Lazo J.S. Effect of anti-calmodulin drugs on the growth and sensitivity of C6 rat glioma cells to bleomycin. Anticancer Res. 14:1994;1711-1721.
46. Aas A.T., Brun A., Pero R.W., Salford L.G. Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth. Br J Neurosurg. 8:1994;187-192.
47. Molnár J., Pusztai R., Hevér A., Nagy S., Motohashi N. Effect of two benzo[a]phenothiazines on multi-drug resistance (mdr) and tumor antigen expression. Anticancer Res. 15:1995;2013-2016.
48. Ford J.M., Prozialeck W.C., Hait W.N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol. 35:1989;105-115.
49. Schleuning M., Brumme V., Wilmanns W. Inhibition of cyclosporine on A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. Naunyn Schmiedebergs Arch Pharmacol. 350:1994;100-103.
50. Petri I.B., Szekeres E., Varga E., Berek I., Molnár J., Berek L., Kawase M., Motohashi N. Immunomodulating activities on cellular cytotoxicity and the blast transformation of human lymphocytes by 10-[n-(phthalimido)alkyl]-2-substituted-10H-phenothiazines and 1-(2-chloroethyl)-3-(2-substituted-10H-phenothiazin-10-yl)alkyl-1-ureas. Anticancer Res. 16:1996;1247-1250.
51. Roudebush R.E., Berry P.L., Layman N.K., Butler L.D., Bryant H.U. Dissociation of immunosuppression by chlorpromazine and trifluoperazine from pharmacologic activities as dopamine antagonists. Int J Immunopharmacol. 13:1991;961-968.
52. Chernavsky A.C., Valerani A.V., Burdman J.A. Haloperidol and oestrogens induce c-myc and c-fos expression in the anterior pituitary gland of the rat. Neurol Res. 15:1993;339-343.
53. Veys P.A., Wilkes S., Shah S., Noyelle R., Hoffbrand A.V. Clinical experience of clozapine-induced neutropenia in the UK. Laboratory investigation using liquid culture systems and immunofluorocytometry. Drug Saf. 7:(Suppl 1):1992;26-32.
54. Abdul M., Logothetis C.J., Hoosein N.M. Growth inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol. 154:1995;247-250.
55. Pellegrino T.C., Bayer B.M. Modulations of immune cell function following fluoxetine administration in rats. Pharmacol Biochem Behav. 59:1998;151-157.
56. Brandes L.J., Arron R.J., Boydanovica R.P., Tony J., Zabioniayh C.L., Hogg G.R. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52:1992;3796-3800.
57. Davies J.A., Garrod D.R. Induction of early stages of kidney tubule differentiation by lithium ions. Dev Biol. 167:1995;50-60.
58. Levay-Young B.K., Amamoto S., Imagawa W., Nandi S. Casein accumulation in mouse mammary epithelial cells after growth stimulated by different hormonal and nonhormonal agents. Endocrinology. 1256:1990;1173-1182.
59. + leukemia cells by lithium chloride. Leuk Res. 17:1993;403-410.
60. Hasgekar N.N., Gohkhale P.P., Amin M.K., Shesadri R., Lalitha V.S. Lithium inhibits growth in a murine neural precursor cell line. Cell Biol Int. 20:1996;781-786.
61. Nordenberg J., Panet C., Wasserman L., Malik Z., Fux A., Stenzel K.H., Novogrodsky A. The anti-proliferative effect of lithium chloride on melanoma cells and its reversion by myo-inositol. Br J Cancer. 55:1987;41-46.
62. Becchetti A., Whitaker M. Lithium blocks cell cycle transitions in the first cell cycles of sea urchin embryos, an effect rescued by myo-inositol. Development. 124:1997;1099-1107.
63. Ballin A., Aladjem M., Banyash M., Biochis H., Barzilay Z., Gal R., Witz I.P. The effect of lithium chloride on tumour appearance and survival of melanoma-bearing mice. Br J Cancer. 48:1983;83-87.
64. Fearon K.C.H., Falconer J.S., Ross J.A., Carter D.C., Hunter J.O., Reynolds P.D., Tuffnell Q. An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate. Anticancer Res. 16:1996;867-874.
65. Taylor J.A., Grady L.H., Engler K.B., Welshons W.V. Relationship of growth stimulated by lithium, estradiol, and EGF to phospholipase C activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 34:1995;265-277.
66. Welshons W.V., Engler K.S., Taylor J.A., Grady L.H., Curran E.M. Lithium-stimulated proliferation and alteration of phosphoinositide metabolites in MCF-7 human breast cancer cells. J Cell Physiol. 165:1995;134-144.
67. Kleinerman E.S., Knowles R.D., Blick M.B., Zwelling L.A. Lithium chloride stimulates human monocytes to secrete tumor necrosis factor/cachectin. J Leukoc Biol. 46:1989;484-492.
68. Richman C.M., Makii M.M., Weiser P.A., Herbst A.L. The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. Am J Hematol. 16:1984;313-323.
69. Gallicchio V.S., Hughes N.K., Hulette B.C., Noblitt L. Effect of interleukin-1, GM-CSF, erythropoietin and lithium on the toxicity associated with 3′-azido-3′-deoxythymidine (AZT) in vitro on hematopoietic progenitors (CFU-GM, CFU-MEG, and BFU-E) using murine retrovirus-infected hematopoietic cells. J Leukoc Biol. 50:1991;580-586.
70. Gallicchio V.S., Hughes N.K., Tse K.F. Modulation of the haematopoietic toxicity associated with zidovudine in vivo with lithium carbonate. J Intern Med. 233:1993;259-268.
71. Wu Y., Cai D. Study of the effect of lithium on lymphokine-activated killer cell activity and its antitumor growth. Proc Soc Exp Biol Med. 201:1992;284-288.
72. Gallicchio V.S., Messino M.H., Hulette B.C., Hughes N.K. Lithium and hematopoiesis Effective experimental use of lithium as an agent to improve bone marrow transplantation . J Med. 23:1992;195-216.
73. Courage-Maguire C., Bacon C.L., Nau H., Regan C.M. Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues. Int J Dev Neurosci. 15:1997;37-43.
74. Martin M.L., Regan C.M. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 554:1991;223-228.
75. Cinatl J. Jr, Cinatl J., Scholz M., Driever P.H., Henrich D., Kabickova H., Vogel J.U., Doerr H.W., Kornhuber B. Antitumor activity of sodium valproate in cultures of human neuroblastoma cells. Anticancer Drugs. 7:1996;766-773.
76. Tittle T.V., Schaumann B.A. Effect of antiepileptic drugs on growth of murine lymphoid tumor cells in single-cell culture. Epilepsia. 33:1992;729-735.